MAXOLON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Maxolon, and what generic alternatives are available?
Maxolon is a drug marketed by King Pharms and is included in one NDA.
The generic ingredient in MAXOLON is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Maxolon
A generic version of MAXOLON was approved as metoclopramide hydrochloride by TEVA on July 29th, 1985.
Summary for MAXOLON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 179 |
Clinical Trials: | 3 |
Patent Applications: | 3,990 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MAXOLON at DailyMed |
Recent Clinical Trials for MAXOLON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sanofi | Phase 3 |
Singapore General Hospital | Phase 3 |
National University Hospital, Singapore | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for MAXOLON
US Patents and Regulatory Information for MAXOLON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | MAXOLON | metoclopramide hydrochloride | TABLET;ORAL | 070106-001 | Mar 4, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |